SEC Filing Summary: Lloyds Banking Group Plc (Form 13F-HR)
Business Context and Reporting Period
This filing is a Form 13F Holdings Report submitted by Lloyds Banking Group Plc, an institutional investment manager based in Edinburgh, Scotland. The report covers the calendar quarter ended June 29, 2012, and was signed on July 25, 2012. The filing includes holdings managed by Lloyds Banking Group Plc and three other included managers: Scottish Widows Investment Partnership Limited, Lloyds TSB Offshore Private Clients Limited, and Lloyds TSB Offshore Limited.
Key Financial Metrics
As this is a Form 13F filing, it reports equity holdings rather than the operating financial performance (revenue, profit, cash flow) of Lloyds Banking Group itself. The following metrics relate to the reported investment portfolio:
- Total Portfolio Value: $9,149,054 (in thousands), totaling approximately $9.15 billion.
- Total Number of Holdings: 629 entries.
- Exchange Rate Used: 1.5686 (GBP to USD).
- Top Holdings by Value:
- Pfizer Inc: $11,735,870 (thousands)
- Wells Fargo & Co: $6,792,166 (thousands)
- General Electric Co: $6,163,608 (thousands)
- Interpublic Group Cos Inc: $5,717,180 (thousands)
- Bank of America Corp: $5,310,573 (thousands)
Note: The filing does not provide data on Lloyds Banking Group's own revenue, profit margins, debt levels, or liquidity.
Material Changes and Portfolio Composition
The filing provides a snapshot of holdings as of the quarter-end date. It does not contain comparative data against the prior quarter to determine material changes in position size or portfolio composition. The portfolio is heavily diversified across sectors, with significant exposure to:
- Financials: Wells Fargo, Bank of America, Citigroup, JPMorgan Chase, PNC Financial Services.
- Healthcare/Pharma: Pfizer, Johnson & Johnson, Merck, UnitedHealth Group.
- Technology: Microsoft, Intel, Cisco Systems, Oracle, Apple.
- Energy: Exxon Mobil, Chevron, Occidental Petroleum.
- Consumer Staples: Walmart, Coca-Cola, Procter & Gamble.
Guidance, Outlook, and Risks
Guidance and Outlook: Form 13F filings are regulatory disclosures of past holdings and do not contain forward-looking guidance, management commentary, or strategic outlooks for the reporting manager.
Risks and Contingencies: The filing does not disclose specific risk factors or contingencies. However, the concentration of holdings in large-cap U.S. equities implies exposure to U.S. market volatility and sector-specific risks prevalent in mid-2012.
Unusual Items: The filing lists holdings with "Defined" voting authority and "Sole" manager authority for the vast majority of positions. No unusual items or restatements were indicated in the cover page.
Key Facts for Investor Verification
- Portfolio Scale: Verify the total reported value of ~$9.15 billion against Lloyds' broader asset management capabilities.
- Top Concentrations: Confirm the significant positions in Pfizer (~$11.7B) and Wells Fargo (~$6.8B) to understand sector weighting.
- Reporting Scope: Note that this report aggregates holdings for Lloyds Banking Group and three subsidiary managers (Scottish Widows, Lloyds TSB Offshore entities).
- Timing: The data reflects positions as of June 29, 2012; verify if subsequent filings (13F-HR for Q3 2012) show significant turnover.
- Currency Conversion: The portfolio value is converted to USD using an exchange rate of 1.5686; verify the impact of GBP/USD fluctuations on the reported value.